Trial Profile
A multicenter randomized controlled trial comparing the efficacy and safety of lamivudine-adefovir combinational therapy with adefovir monotherapy for chronic hepatitis B and cirrhosis with lamivudine-resistance.
Status:
Recruiting
Phase of Trial:
Phase III
Latest Information Update: 09 May 2017
Price :
$35
*
At a glance
- Drugs Adefovir (Primary) ; Lamivudine (Primary)
- Indications Hepatitis B; Liver cirrhosis
- Focus Therapeutic Use
- 03 Oct 2011 Planned end date added Dec 2011 as reported by University Hospital Medical Information Network - Japan record.
- 02 Aug 2007 New trial record.